
Kim R M Blenman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/511956/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2587-2597.	7.0	16
2	Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer. Cancer Causes and Control, 2022, 33, 831-841.	1.8	3
3	Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research, 2022, 82, 1698-1711.	0.9	4
4	Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open, 2022, 12, e055735.	1.9	9
5	ISAC Probe Tag Dictionary: Standardized Nomenclature for Detection and Visualization Labels Used in Cytometry and Microscopy Imaging. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 103-106.	1.5	3
6	Data File Standard for Flow Cytometry, Version <scp>FCS</scp> 3.2. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 100-102.	1.5	6
7	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research, 2021, 27, 5299-5306.	7.0	39
8	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers, 2021, 13, 4839.	3.7	18
9	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature, 2021, 598, 682-687.	27.8	117
10	Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. , 2020, 8, e001558.		85
11	PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. Clinical Cancer Research, 2020, 26, 5456-5461.	7.0	60
12	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
13	Pathology of spontaneous and immunotherapyâ€induced tumor regression in a murine model of melanoma. Pigment Cell and Melanoma Research, 2019, 32, 448-457.	3.3	13
14	Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue Cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 399-410.	1.5	13
15	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 2442-2449.	7.0	106
16	Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. Npj Breast Cancer, 2018, 4, 28.	5.2	20
17	Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High-Resolution Multispectral Imaging to Predict Metastasis. Methods in Molecular Biology, 2014, 1102, 601-621.	0.9	7